Investigation of the Impact of the H310A FcRn Region Mutation on ⁸⁹Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody.

ABSTRACT:

Purpose

In the emerging field of antibody treatments for neurodegenerative diseases, reliable tools are needed to evaluate new therapeutics, diagnose and select patients, monitor disease progression, and assess therapy response. Immuno-PET combines the high affinity and exceptional specificity of monoclonal antibodies with the non-invasive imaging technique positron emission tomography (PET). Its application in neurodegenerative disease brain imaging has been limited due to the marginal uptake across the blood-brain barrier (BBB). The emergence of BBB-shuttle antibodies with enhanced uptake across the BBB extended immuno-PET to brain imaging. We recently reported about specific brain uptake of a bispecific aducanumab mTfR antibody in APP/PS1 TG mice using ⁸⁹Zr-immuno-PET

SUBMITTER: Wuensche TE 

PROVIDER: S-EPMC11436416 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature